Abstract
Several authors have made the intriguing observation that Implantable Cardioverter Defibrillators (ICD) appear not only to reduce sudden deaths, but also mortality due to non-arrhythmic causes. Studies have shown that this observation can not be attributed to patient selection bias. In trying to explain this apparent anomaly, it should be noted that two treatment strategies are being compared.
Thus, it might be that, under certain circumstances, antiarrhythmic drugs contribute
to non-arrhythmic deaths, not that ICDs reduce them. There appear to be some plausible explanations for this phenomenon, e.g., the long-term effect on cardiac function of episodes of ventricular tachycardia lasting for several hours for patients treated solely by antiarrhythmic drugs, compared to their quick termination by an ICD. However, further research into this curious mode of death
issue is needed, and may provide further insights into patient populations deriving greatest benefit from one therapy or the other.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mirowski M, Reid P, Mower M, Watkins L, Gott V, Schauble J, Langer A, Heilman M, Kolenik S, Fischell R, Weisfeldt M. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322-324.
Taskforce for ACC/AHA Practice Guidelines. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol 1998;31:1175-1209.
Saksena S, Parsonnet V. Implantation of a cardioverter/ defibrillator without thoracotomy using a triple electrode system. JAMA 1988;259:69-72.
Nisam S. Technology update: The modern implantable cardioverter defibrillator. Ann Noninvasive Electrocardiography 1997;2:69-78.
Wever E, Hauer R, Van Capelle F, Tijssen J, Crijns H, Algra A, Wiesfeld A, Bakker P, Robles de Medina E. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-2203.
Moss A, Hall J, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M, for the MADIT Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmias. N Engl J Med 1996;335:1933-1940.
The Antiarrhythmic Versus Implantable Defibrillator (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
Kuck K-H, Cappato,. R. Implantable heart defibrillator saves lives in patients with previous cardiac arrest. Oral presentation during “Hotline session: new-breaking clinical trials,” at 47th annual scientific sessions of the American College of Cardiology meeting, Atlanta, GA. (Press Release, 30 March 1998).
Connolly, S. Results from the Canadian Implantable De-fibrillator Study (CIDS). Oral presentation during “Hotline session: new-breaking clinical trials,” at 47th annual scientific sessions of the American College of Cardiology meeting, Atlanta, GA. (Press Release, 30 March 1998).
Marchlinski_ F, Gottlieb C, Sarter B, Finkle J, Hook B, Callans D, Schwartzman D. ICD data storage: Value in arrythmia management. PACE 1993;16:527-534. Also: Sweeney M, Ruskin J. Mortality benefits and the implantable cardioverter defibrillator. Circulation 1994;89:1851-1858.
Sweeney M, Ruskin J. Mortality benefits and the implantable cardioverter defibrillator. Circulation 1994;89:1851-1858.
Epstein A. Letter to the editor (re.AVID Trial). PACE 1994; 17:262-266.
Estes M. Clinical strategies for use of the implantable cardioverter defibrillator: The impact of current trials. PACE 1996;19:1011-1015.
Herre J, Sauve M, Malone P, Griffin J, Helmy I, Langberg J, Goldberg H, Scheinman M. Long-term results of amiodarone therapy with recurrent sutained ventricular tachycardia or ventricular fibrillation. J Am Coll Card 1989;13: 442-449.
Winkle R, Mead H, Ruder M, Gaudiani V, Smith N, Buch W, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardioverter defibrillator. J Am Coll Cardiol 1989;13:1353-1361.
Newman D, Sauve J, Herre J, Lanberg J, Lee M, Titus C, Scheinman M. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992;69:889-903.
Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997;337:1569-1575.
Powell A, Finkelstein D, Garan H, Fuchs T, Cannom D, McGovern B, Kelly P, Vlahakes G, Torchiana D, Ruskin J. Influence of implantable cardioverter defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-1092.
Josephson M, Nisam S. Prospective trials of implantable cardioverter defibrillators versus drugs: Are they addressing the right question? Am J Cardiol 1996;77:859-863.
Nisam S. Do MADIT results apply only to “MADIT Patients”? Am J Cardiol 1997;79 (6A):27-30.
Julian D, Camm J, Frangin G, Janse M, Munoz A, Schwartz P, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
Rights and permissions
About this article
Cite this article
Nisam, S. Can Implantable Defibrillators Reduce Non-arrhythmic Mortality?. J Interv Card Electrophysiol 2, 371–375 (1998). https://doi.org/10.1023/A:1009720906851
Issue Date:
DOI: https://doi.org/10.1023/A:1009720906851